JLK, a medical artificial intelligence (AI) company, announced on the 28th that it has obtained Japanese approval for its brain MRI imaging AI solution, 'JLK-GRE'. With this approval, JLK now holds a total of six medical imaging AI solution approvals in Japan, expanding its portfolio in the local market.
'JLK-GRE' is a solution that automatically detects and analyzes low-intensity areas in GRE (Gradient Echo) images of brain MRI, and provides the information to medical staff with intuitive visualization. The analysis results are immediately provided through the hospital's PACS (Picture Archiving and Communication System) and user interface (UI), supporting fast and accurate diagnostic decisions by medical staff.
With the approval of 'JLK-GRE', JLK plans to strengthen its diverse portfolio of medical imaging AI solutions and increase its competitiveness in the Japanese market. JLK's medical imaging AI solutions include 'JLK-CTP', 'JLK-PWI', 'JLK-NCCT', 'JLK-FLAIR', and 'JLK-DWI', and expansion of contracts with local hospitals is expected.
The company is currently pursuing collaboration with a medical specialist company affiliated with a large local general trading company to advance into the Japanese market. This partner company has strengths in medical device distribution and hospital networks in Japan, so it is expected to play an important role in expanding JLK’s local sales. In addition, JLK recently invited Professor Manabu Inoue of the National Cardiovascular Center in Japan and Professor Chi-kyung Kim of Korea University Guro Hospital to host a Korea-Japan Stroke Web Symposium, thereby accelerating its entry into the Japanese market.
Kim Dong-min, CEO of JLK, said, “This JLK-GRE approval in Japan is an important turning point that will allow us to actively target Japan’s MRI-centered clinical environment,” and added, “We will accelerate contracts with local hospitals by expanding our MRI-based solutions and lead to actual sales growth.”
- See more related articles
You must be logged in to post a comment.